Who is the CEO of Union Korea Pharm?

According to the DART company overview, Union Korea Pharm's representative director is 성광현 (name as registered in Korean). The company was founded on 1985-08-10.

Where is Union Korea Pharm listed?

Union Korea Pharm trades on the Korea Exchange KOSDAQ market under the ticker 080720. Its fiscal year ends in December.

Does Union Korea Pharm pay a dividend?

Union Korea Pharm did not pay a cash dividend for fiscal 2025, according to its annual report.

Does Union Korea Pharm have any recent filing signals?

Signals detected automatically from DART filings and quarterly results: Dilution risk (rights offering or CB/BW/EB issue decided in the past 90 days); 4 quarters of losses (operating loss in each of the last four quarters); Private placement (third-party allotment rights offering decided in the past 90 days). 1 more signal is shown on the page. These are factual flags, not investment advice.

Which companies are in the same industry as Union Korea Pharm?

Under the Korean Standard Industrial Classification recorded on DART, Union Korea Pharm is grouped with 107 other listed companies in pharmaceuticals. The most covered in Korean news over the past 30 days are Hanmi Pharm, Yuhan and Daewoong Pharma.

Union Korea Pharm KRX:080720KOSDAQ

한국유니온제약 · Korean news coverage and regulatory filings, organized.

한국어

Articles, 24h0

Articles, 7 days0

DART filings, 7 days1

Articles tracked37since Sep 11

In Q2 2026, Union Korea Pharm reported revenue of ₩5.9bn, down 41.4% year on year, and an operating loss of ₩1.3bn. Union Korea Pharm (한국유니온제약) appeared in 0 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Oct 21 with 4 articles.

Filing signals Private placement Dilution risk 4 quarters of losses Capital reduction Screener

Union Korea Pharm quarterly results consolidated, KRW

Quarter	Revenue	YoY	Operating profit	Net income
Q2 2026	₩5.9bn	-41.4%	−₩1.3bn margin −21.1%	₩2.1bn
Q1 2026	₩5.9bn	-53.2%	−₩1.6bn margin −26.5%	−₩2.3bn
Q4 2025 derived	₩6.5bn	+64.8%	−₩2.6bn margin −40.9%	−₩13.1bn
Q3 2025	₩7.1bn	-54.8%	−₩9.9bn margin −139.0%	−₩11.0bn
Q2 2025	₩10.2bn	-32.5%	−₩2.9bn margin −28.5%	−₩4.1bn
Q1 2025	₩12.6bn	-23.7%	−₩1.8bn margin −14.1%	−₩2.6bn
Q4 2024 derived	₩3.9bn	-76.5%	−₩7.8bn margin −197.5%	−₩12.7bn
Q3 2024	₩15.8bn	-0.8%	−₩1.9bn margin −12.3%	−₩1.3bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Union Korea Pharm top stories 2 weeks, by number of outlets

1
[공시] 한국유니온제약 주요사항보고서(감자결정)
1 outlets · 1 articlesFirst report Oct 21 11:18 스페셜타임스
2
한국유니온제약, 회생채권 출자전환…신주 발행 후 감자 추진
1 outlets · 1 articlesFirst report Oct 21 13:27 메디파나뉴스
3
한국유니온제약, 잔여 채무 1억 원대 출자전환…상장 유지 험로 뚫을까
1 outlets · 1 articlesFirst report Oct 21 17:27 바이오타임즈
4
한국유니온제약, 유상증자…유수민 등에 3자 배정
1 outlets · 1 articlesFirst report Oct 21 11:06 연합뉴스경제
5
한국유니온제약, 회생채권 출자전환 36만5003주 발행
1 outlets · 1 articlesFirst report Oct 22 06:06 비건뉴스

Latest Union Korea Pharm news Korean headlines

Oct 2206:06

한국유니온제약, 회생채권 출자전환 36만5003주 발행
비건뉴스
Oct 2117:27

한국유니온제약, 잔여 채무 1억 원대 출자전환…상장 유지 험로 뚫을까
바이오타임즈
Oct 2113:27

한국유니온제약, 회생채권 출자전환…신주 발행 후 감자 추진
메디파나뉴스
Oct 2111:18

[공시] 한국유니온제약 주요사항보고서(감자결정)
스페셜타임스
Oct 2111:06

한국유니온제약, 유상증자…유수민 등에 3자 배정
연합뉴스경제
Oct 1121:19
부광약품, 한국유니온제약 ‘부광유니파마’로 사명 변경
비즈트리뷴Bukwang Pharmaceutical IND
1 more on this story · 1 outlets
- 부광약품 한국유니온제약, 부광유니파마로 사명 변경메디칼업저버 · Oct 12 05:57
Oct 914:49

부광, 한국유니온제약, 부광유니파마로 사명 변경
스페셜경제
Oct 816:25
한국유니온제약, ‘부광유니파마’로 새 출발
한스경제
1 more on this story · 1 outlets
- 부광약품 인수 한국유니온제약, '부광유니파마'로 새 출발뉴스핌 · Oct 8 17:35
Oct 816:22

부광 "한국유니온제약, '부광유니파마'로 사명변경"
뉴시스경제
Oct 816:15
부광약품에 인수된 한국유니온제약, ‘부광유니파마’로 새출발
딜사이트Bukwang Pharmaceutical IND
1 more on this story · 1 outlets
- 부광약품에 인수된 한국유니온제약, '부광유니파마'로 새 출발코메디닷컴 · Oct 8 18:22
Oct 816:13

한국유니온제약, 이제 '부광유니파마'로
히트뉴스
Oct 815:55

부광약품, 한국유니온제약 간판 바꿨다…‘부광유니파마’ 출범
아시아투데이Bukwang Pharmaceutical IND
Oct 815:36
부광약품, 한국유니온제약 '부광유니파마'로 사명 변경
EBNBukwang Pharmaceutical IND
16 more on this story · 15 outlets
- 한국유니온제약, 임시주총서 ‘부광유니파마’로 사명 변경PRESS9 · Oct 8 15:45
- 부광약품, 자회사 '유니온제약→부광유니파마' 사명 변경MTN · Oct 8 15:58
- 부광약품, 한국유니온제약 '부광유니파마'로 사명 변경뉴스1 · Oct 8 16:00
- 부광약품, 한국유니온제약 ‘부광유니파마’로 사명 변경메디포뉴스 · Oct 8 16:08
- 부광약품, 한국유니온제약 사명 '부광유니파마'로 변경연합뉴스경제 · Oct 8 16:12
- 한국유니온제약, '부광유니파마'로 사명 변경…"부광약품 생산력 강화"머니투데이 · Oct 8 16:24
- 한국유니온제약, '부광유니파마'로 사명 변경메디파나뉴스 · Oct 8 16:28
- 부광약품, 한국유니온제약 사명 ‘부광유니파마’로 변경…생산체계 재편이데일리 · Oct 8 16:29
- 부광약품, 한국유니온제약 사명 ‘부광유니파마’로 변경…생산체계 재편이데일리 · Oct 8 16:30
- 부광약품, 한국유니온제약 ‘부광유니파마’로 사명 변경브릿지경제 · Oct 8 16:32
- 부광약품 “한국유니온제약, ‘부광유니파마’로 사명 변경”더바이오 · Oct 8 16:35
- 부광약품, 한국유니온제약 사명 '부광유니파마'로 변경아시아경제 · Oct 8 16:56
- +4
Sep 2809:18

사명 바뀌는 한국유니온제약, 지배구조 정비…법률전문가 감사 선임
PRESS9
Sep 2108:54

한국유니온제약, '부광유니파마'로 새 출발…경영 정상화 속도
EBN
Sep 1912:50

[제약공시 책갈피] 9월 3주차 - 보령·한국유니온제약 外
메디파나뉴스Boryung
Sep 1709:10

한국유니온제약, '부광유니파마'로 새출발…부광약품 인수 마무리 수순
메디팜스투데이Bukwang Pharmaceutical IND
Sep 1709:06

'부광유니파마'로 새 출발하는 한국유니온제약…남은 과제는 '실적 정상화'
PRESS9
Sep 1616:04

한국유니온제약, '부광유니파마'로 상호 변경 추진
PRESS9

Articles per day 2 weeks

421

122

Company profile

CEO: 성광현
Industry: Pharmaceuticals
Founded: 1985-08-10
Fiscal year-end: December
Head office: 강원도 원주시
Website: ukp.co.kr
Quotes & chart: Naver Securities (Korean)

From the DART company overview.

Same industry Pharmaceuticals

All in industry

Company	Latest quarter op. profit	Articles 30d
Hanmi Pharm	₩131bn	655
Yuhan	₩66.9bn	484
Daewoong Pharma	₩68.1bn	372
GC Biopharma	₩1.7bn	326
DongKookPharmaceutical	₩26.1bn	259
Daewon Pharmaceutical	−₩9m	197
Kwangdong Pharmaceutical	₩2.8bn	188
JW Pharmaceutical	₩33.3bn	185

Compare Union Korea Pharm side by side with these companies

Union Korea Pharm DART filings

Oct 2913:42

Other 증권발행결과(자율공시) (제3자배정 유상증자-출자전환)
Other
Oct 2111:05

Capital reduction 주요사항보고서(감자결정)
Capital & M&A
Oct 2111:04

Rights offering 주요사항보고서(유상증자결정)
Capital & M&A
Oct 1214:06

Other [기재정정]반기보고서 (2026.06)
Other
Oct 816:24

Other 상호변경안내
Other
Oct 816:18

Other 임시주주총회결과
Other
Sep 2315:13

Other 의결권대리행사권유참고서류
Other
Sep 2315:06

Other 주주총회소집공고
Other
Sep 1615:58

Other [기재정정]주주총회소집결의
Other

Mentioned alongside 2 weeks

No co-mentioned companies yet.

Union Korea Pharm FAQ

Who is the CEO of Union Korea Pharm?: According to the DART company overview, Union Korea Pharm's representative director is 성광현 (name as registered in Korean). The company was founded on 1985-08-10.
Where is Union Korea Pharm listed?: Union Korea Pharm trades on the Korea Exchange KOSDAQ market under the ticker 080720. Its fiscal year ends in December.
What were Union Korea Pharm's latest quarterly results?: In Q2 2026, Union Korea Pharm reported revenue of ₩5.9bn, down 41.4% year on year, and an operating loss of ₩1.3bn. Figures come from reports filed on DART.
Does Union Korea Pharm pay a dividend?: Union Korea Pharm did not pay a cash dividend for fiscal 2025, according to its annual report.
Does Union Korea Pharm have any recent filing signals?: Signals detected automatically from DART filings and quarterly results: Dilution risk (rights offering or CB/BW/EB issue decided in the past 90 days); 4 quarters of losses (operating loss in each of the last four quarters); Private placement (third-party allotment rights offering decided in the past 90 days). 1 more signal is shown on the page. These are factual flags, not investment advice.
Which companies are in the same industry as Union Korea Pharm?: Under the Korean Standard Industrial Classification recorded on DART, Union Korea Pharm is grouped with 107 other listed companies in pharmaceuticals. The most covered in Korean news over the past 30 days are Hanmi Pharm, Yuhan and Daewoong Pharma.